Schad, F.; Thronicke, A.; Hofheinz, R.-D.; Klein, R.; Grabowski, P.; Oei, S.L.; Wüstefeld, H.; Grah, C.
Immune Checkpoint Blockade Combined with AbnobaViscum® Therapy Is Linked to Improved Survival in Advanced or Metastatic Non-Small-Cell Lung Cancer Patients: A Registry Study in Accordance with the ESMO Guidance for Reporting Real-World Evidence. Pharmaceuticals 2024, 17, 1713.
https://doi.org/10.3390/ph17121713
AMA Style
Schad F, Thronicke A, Hofheinz R-D, Klein R, Grabowski P, Oei SL, Wüstefeld H, Grah C.
Immune Checkpoint Blockade Combined with AbnobaViscum® Therapy Is Linked to Improved Survival in Advanced or Metastatic Non-Small-Cell Lung Cancer Patients: A Registry Study in Accordance with the ESMO Guidance for Reporting Real-World Evidence. Pharmaceuticals. 2024; 17(12):1713.
https://doi.org/10.3390/ph17121713
Chicago/Turabian Style
Schad, Friedemann, Anja Thronicke, Ralf-Dieter Hofheinz, Reinhild Klein, Patricia Grabowski, Shiao Li Oei, Hannah Wüstefeld, and Christian Grah.
2024. "Immune Checkpoint Blockade Combined with AbnobaViscum® Therapy Is Linked to Improved Survival in Advanced or Metastatic Non-Small-Cell Lung Cancer Patients: A Registry Study in Accordance with the ESMO Guidance for Reporting Real-World Evidence" Pharmaceuticals 17, no. 12: 1713.
https://doi.org/10.3390/ph17121713
APA Style
Schad, F., Thronicke, A., Hofheinz, R.-D., Klein, R., Grabowski, P., Oei, S. L., Wüstefeld, H., & Grah, C.
(2024). Immune Checkpoint Blockade Combined with AbnobaViscum® Therapy Is Linked to Improved Survival in Advanced or Metastatic Non-Small-Cell Lung Cancer Patients: A Registry Study in Accordance with the ESMO Guidance for Reporting Real-World Evidence. Pharmaceuticals, 17(12), 1713.
https://doi.org/10.3390/ph17121713
